Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering.

Maffioletti SM, Sarcar S, Henderson ABH, Mannhardt I, Pinton L, Moyle LA, Steele-Stallard H, Cappellari O, Wells KE, Ferrari G, Mitchell JS, Tyzack GE, Kotiadis VN, Khedr M, Ragazzi M, Wang W, Duchen MR, Patani R, Zammit PS, Wells DJ, Eschenhagen T, Tedesco FS. · 2018

Read Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering. by Maffioletti SM, Sarcar S, Henderson ABH, Mannhardt I, Pinton L, Moyle LA, Steele-Stallard H, Cappellari O, Wells KE, Ferrari G, Mitchell JS, Tyzack GE, Kotiadis VN, Khedr M, Ragazzi M, Wang W, Duchen MR, Patani R, Zammit PS, Wells DJ, Eschenhagen T, Tedesco FS. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5917451.txt.

Introduction

Maffioletti and co-authors grow three-dimensional human muscle from stem cells. Their article appeared in Cell Reports. They used induced stem cells from patients with muscular dystrophy. Forms included Duchenne, limb-girdle, and congenital types. Cells grew in hydrogels held under tension. That tension aligned the fibres like real muscle.

The lab muscles matched traits of human skeletal muscle, they report. They could be implanted into mice lacking immunity. Disease hallmarks showed up with high fidelity. Models also included vessel cells and motor neurons. All parts came from human stem cells. The platform may aid drug tests and tissue repair.

Catalog record

CREATORMaffioletti SM, Sarcar S, Henderson ABH, Mannhardt I, Pinton L, Moyle LA, Steele-Stallard H, Cappellari O, Wells KE, Ferrari G, Mitchell JS, Tyzack GE, Kotiadis VN, Khedr M, Ragazzi M, Wang W, Duchen MR, Patani R, Zammit PS, Wells DJ, Eschenhagen T, Tedesco FS.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE49 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5917451

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering By Sara Martina Maffioletti, Shilpita Sarcar, Alexander B.H. Henderson, Ingra Mannhardt, Luca Pinton, Louise Anne Moyle, Heather Steele-Stallard, Ornella Cappellari, Kim E. Wells, Giulia Ferrari, Jamie S. Mitchell, Giulia E. Tyzack Published in: Cell Reports DOI: 10.1016/j.celrep.2018.03.091 ABSTRACT Summary Generating human skeletal muscle models is instrumental for investigating muscle pathology and therapy. Here, we report the generation of three-dimensional (3D) artificial skeletal muscle tissue from human pluripotent stem cells, including induced pluripotent stem cells (iPSCs) from patients with Duchenne, limb-girdle, and congenital muscular dystrophies. 3D skeletal myogenic differentiation of pluripotent cells was induced within hydrogels under tension to provide myofiber alignment. Artificial muscles recapitulated characteristics of human skeletal muscle tissue and could be implanted into immunodeficient mice. Pathological cellular hallmarks of incurable forms of severe muscular dystrophy could be modeled with high fidelity using this 3D platform. Finally, we show generation of fully human iPSC-derived, complex, multilineage muscle models containing key isogenic cellular constituents of skeletal muscle, including vascular endothelial cells, pericytes, and motor neurons. These results lay the foundation for a human skeletal muscle organoid-like platform for disease modeling, regenerative medicine, and therapy development. INTRODUCTION Skeletal muscle is the most abundant human tissue, and it is responsible for movement, posture, temperature control, and various metabolic functions. It is composed of aligned multinucleated myofibers, and its repair and regeneration rely on resident stem or progenitor cells, of which satellite cells are the best characterized (Tedesco et al., 2010). Nonetheless, impaired muscle regeneration occurs in acute or chronic conditions, such as significant trauma (Grogan et al., 2011), or incurable inherited disorders, such as muscular dystrophies (Mercuri and Muntoni, 2013). Artificial human skeletal muscles would provide an invaluable tool to study pathological mechanisms, test potential therapeutics, and develop tissue replacement protocols. Use of a similar approach in other tissues has proved transformational for drug development and regenerative medicine by means of organoid technology (Fatehullah et al., 2016, Lancaster and Knoblich, 2014). Although several studies have reported methods to engineer rodent skeletal muscle tissue (Carosio et al., 2013, Corona et al., 2014, Huang et al., 2005, Juhas et al., 2014, Machingal et al., 2011, Shandalov et al., 2014, VanDusen et al., 2014), fewer groups have used human cells (Chiron et al., 2012, Fuoco et al., 2015, Madden et al., 2015, Powell et al., 1999, Quarta et al., 2017, Tchao et al., 2013). Apart from a recent study on healthy donor human pluripotent stem cells (hPSCs) for muscle tissue engineering (Rao et al., 2018), most studies used primary human cells from invasive muscle biopsies, facing hurdles such as poor cell availability, limited cell expansion potential, and exhaustion of differentiation ability. In addition, although there is an increasing need to develop clinically relevant multilineage patient-specific models (Giacomelli et al., 2017), no such isogenic human skeletal muscle model has been derived to date. These obstacles hinder the translational potential of these platforms for muscle diseases. To overcome these limitations, here we have exploited the virtually unlimited proliferative capacity and controllable differentiation of human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) (referred to collectively as hPSCs) (Inoue et al., 2014) to produce 3D artificial skeletal muscle constructs for complex muscle disease modeling. hPSCs were induced to skeletal myogenesis within a biocompatible hydrogel using established protocols (Caron et al., 2016, Maffioletti et al., 2015, Tedesco et al., 2012). Artificial muscles could be made using hiPSCs from Duchenne, limb-girdle type 2D, and LAMIN A/C (LMNA)-related muscular dystrophies. Our 3D platform modeled cellular hallmarks of LMNA-related muscular dystrophies with high fidelity. Finally, essential cell types present in muscle tissue, such as vascular cells and motor neurons, were derived from the same hiPSC source to generate isogenic multilineage muscle constructs. RESULTS 3D Artificial Muscles Can Be Generated from Multiple Healthy and Dystrophic hPSC Lines To generate 3D human artificial skeletal muscles, hPSC-derived myogenic cells (healthy and dystrophic) (Figure 1A) were embedded in fibrin hydrogels and differentiated, adapting a cardiac tissue engineering platform (Hansen et al., 2010). Fibrin was polymerized from fibrinogen in molds between two flexible silicone posts providing continuous tension to the gel, sufficient to direct orientation of cells along the force axis (Figure 1B). Over 10 days, cells remodeled the matrix, generating a 7–8 mm long strip of tissue containing structures resembling skeletal myofibers (Figures 1C, 1D, and S1A). Both transgene-based (Maffioletti et al., 2015) and transgene-free (Caron et al., 2016) differentiation protocols produced muscle constructs (Figures 2A and S1B). Transgene-based muscle constructs were generally used due to the better alignment of myofibers, easier scalability of cultures, and experimental cost-effectiveness.Figure 1Differentiation of Multiple hPSC Lines into Skeletal Myotubes and Remodeling of Fibrin Hydrogels upon 3D Culture(A) Immunofluorescence analysis for myosin heavy chain (MyHC) in standard monolayer cultures of differentiated hESC- and hiPSC-derived cells (DMD, Duchenne muscular dystrophy; LGMD2D, limb-girdle muscular dystrophy type 2D; LMNA, skeletal muscle laminopathies, specific mutations listed).(B) Side-view of the 3D culture platform with freshly polymerized gels at day 0 (left) and day 10 (right) of culture containing hiPSC-derived myogenic cells.(C) Representative phase contrast images of cellularized hydrogels after polymerization (day 0) and after 10 days in culture. Gels undergo remodeling, shorten, and thin in culture (graph). Mean ± SD, N = 2–4 per time point.(D) H&E staining of a transverse hydrogel sections after 10 days of differentiation.Magnification: centronucleated myofibers. Scale bars: (A and D) 100 μm; (C) 1 mm.Figure 23D Artificial Skeletal Muscle Constructs Derived from Healthy and Dystrophic hPSCs(A) Whole-mount immunofluorescence for myosin heavy chain (MyHC) on muscle constructs derived from hESCs, WT hiPSCs (transgene-based and transgene-free differentiation protocols) and dystrophic hiPSCs (DMD, LGMD2D, and skeletal muscle LMNA) differentiated in 3D for 10 days. Nuclei are counterstained with Hoechst. Arrowheads: multinucleated myotubes.(B) Graph quantifying the proportion of MyHC+ cells using z stack confocal microscopy of three hPSC lines shown in (A).(C) Immunolabeling for LAMININ (extracellular matrix), MyHC, and nuclei (Hoechst) on DMD artificial muscles.(D) Western blot for MyHC (250 kDa) in undifferentiated and 3D differentiated iPSC-derived, inducible myogenic cells. β-tubulin: loading control (50 kDa).(E) qRT-PCR analysis of artificial muscles for myogenic markers. DYSTROPHIN (DYS) is absent from DMD-derived artificial muscles. N = 3 for all lines apart from LMNA mutant and LGMD2D hiPSCs, whose error bars represent intra-experimental replicates (n = 3). Values are normalized on GAPDH expression; ΔΔCt is calculated on the corresponding expression values of undifferentiated cells.(F) Immunohistochemistry for sarcomeric actin in DMD artificial muscles after 10 days of differentiation.(G) Transmitted electron microscopy images of DMD iPSC-derived artificial muscle showing sarcomeres (white arrowheads: z lines).(H) Immunofluorescence showing PAX7+ nuclei adjacent to DESMIN+ myofibers following transgene-free commitment and differentiation of hiPSCs in 3D for 14 days. The graph quantifies the percentage of PAX7+ nuclei within the hydrogels (a total of 5,341 nuclei across 10 random fields).(I) Bright-field image of a tibialis anterior (TA) muscle 1 week after implantation of artificial muscles generated using GFP+ myogenic cells. Dashed rectangle: grafted area.(J) Immunofluorescence showing engrafted human nuclei (LAMIN A/C+, left) corresponding to an area in a serial section with embryonic MyHC+ (eMyHC) fibers in transverse sections of a TA muscle 1 week after implantation. Right graphs show quantification of human nuclei from three healthy or dystrophic cell

Read the complete text